Biotechnology · Waltham, Massachusetts, United States
$0.22
-9.71% (-$0.02)2026-10-13
Revenue$1.1M
Net Income-$30.4M
EPS$-0.45
Price Performance
Historical data including institutional events
Company Profile
G
Gavin MacBeath
CEO & Executive Director
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The companyâs lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohnâs disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
- Founded
- 2018
- Employees
- 142
- Headquarters
- Waltham, Massachusetts, United States
- Website
- www.tscan.com
Peer ComparisonRevenue ($B)
▾Loading company sections...